RB Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.75M | Sell |
4,795
-25
| -0.5% | -$25.5K | 1.12% | 20 |
|
|
2026
Q1 | $4.43M | Buy |
4,820
+215
| +5% | +$218K | 0.94% | 28 |
|
|
2025
Q4 | $4.95M | Buy |
4,605
+8
| +0.2% | +$7.65K | 0.98% | 23 |
|
|
2025
Q3 | $3.51M | Buy |
4,597
+93
| +2% | +$69.2K | 0.72% | 34 |
|
|
2025
Q2 | $3.51M | Buy |
4,504
+285
| +7% | +$221K | 0.8% | 31 |
|
|
2025
Q1 | $3.48M | Buy |
4,219
+204
| +5% | +$170K | 0.81% | 29 |
|
|
2024
Q4 | $3.1M | Buy |
4,015
+180
| +5% | +$149K | 0.71% | 35 |
|
|
2024
Q3 | $3.4M | Buy |
3,835
+868
| +29% | +$780K | 0.79% | 33 |
|
|
2024
Q2 | $2.69M | Buy |
2,967
+238
| +9% | +$190K | 0.66% | 39 |
|
|
2024
Q1 | $2.12M | Buy |
2,729
+243
| +10% | +$173K | 0.56% | 45 |
|
|
2023
Q4 | $1.45M | Buy |
2,486
+282
| +13% | +$165K | 0.42% | 58 |
|
|
2023
Q3 | $1.18M | Sell |
2,204
-16
| -0.7% | -$8.24K | 0.37% | 62 |
|
|
2023
Q2 | $1.04M | Sell |
2,220
-55
| -2% | -$23.1K | 0.31% | 71 |
|
|
2023
Q1 | $781K | Buy |
2,275
+59
| +3% | +$19.9K | 0.25% | 84 |
|
|
2022
Q4 | $811K | Buy |
2,216
+141
| +7% | +$50K | 0.29% | 76 |
|
|
2022
Q3 | $671K | Sell |
2,075
-307
| -13% | -$97.3K | 0.26% | 81 |
|
|
2022
Q2 | $772K | Buy |
2,382
+33
| +1% | +$9.91K | 0.29% | 76 |
|
|
2022
Q1 | $673K | Buy |
2,349
+32
| +1% | +$8.23K | 0.22% | 85 |
|
|
2021
Q4 | $640K | Buy |
2,317
+1
| +0% | +$254 | 0.2% | 84 |
|
|
2021
Q3 | $535K | Sell |
2,316
-400
| -15% | -$98.7K | 0.2% | 93 |
|
|
2021
Q2 | $623K | Sell |
2,716
-107
| -4% | -$21.5K | 0.24% | 88 |
|
|
2021
Q1 | $527K | Sell |
2,823
-753
| -21% | -$147K | 0.23% | 90 |
|
|
2020
Q4 | $604K | Sell |
3,576
-121
| -3% | -$18.1K | 0.28% | 77 |
|
|
2020
Q3 | $542K | Sell |
3,697
-40
| -1% | -$6.19K | 0.25% | 79 |
|
|
2020
Q2 | $614K | Sell |
3,737
-53
| -1% | -$8.13K | 0.33% | 71 |
|
|
2020
Q1 | $539K | Buy |
3,790
+16
| +0.4% | +$2.2K | 0.35% | 66 |
|
|
2019
Q4 | $497K | Sell |
3,774
-14
| -0.4% | -$1.62K | 0.28% | 76 |
|
|
2019
Q3 | $408K | Buy |
3,788
+14
| +0.4% | +$1.56K | 0.26% | 81 |
|
|
2019
Q2 | $418K | Buy |
3,774
+219
| +6% | +$25.8K | 0.3% | 78 |
|
|
2019
Q1 | $461K | Buy |
3,555
+17
| +0.5% | +$2.07K | 0.38% | 66 |
|
|
2018
Q4 | $409K | Sell |
3,538
-234
| -6% | -$26.1K | 0.41% | 64 |
|
|
2018
Q3 | $405K | Sell |
3,772
-124
| -3% | -$12.4K | 0.36% | 71 |
|
|
2018
Q2 | $332K | Buy |
3,896
+23
| +0.6% | +$1.89K | 0.25% | 88 |
|
|
2018
Q1 | $300K | Sell |
3,873
-441
| -10% | -$35.5K | 0.24% | 90 |
|
|
2017
Q4 | $364K | Buy |
4,314
+24
| +0.6% | +$2.04K | 0.26% | 82 |
|
|
2017
Q3 | $367 | Buy |
4,290
+27
| +0.6% | +$2.21K | ﹤0.01% | 77 |
|
|
2017
Q2 | $351K | Sell |
4,263
-6
| -0.1% | -$490 | 0.3% | 76 |
|
|
2017
Q1 | $359K | Sell |
4,269
-363
| -8% | -$29.1K | 0.34% | 73 |
|
|
2016
Q4 | $341K | Buy |
+4,632
| New | +$345K | 0.34% | 75 |
|
Other funds holding LLY
RB Capital Management's LLY Position: Q2 2026 in Review
RB Capital Management reduced its Eli Lilly (LLY) stake by 0.52% in Q2 2026, selling an estimated $25.5K and leaving 4,795 shares worth $5.75M. The position accounts for 1.12% of the portfolio, ranked #20.
RB Capital Management first reported a position in LLY in Q4 2016 and has held it in 39 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- RB Capital Management held 4,795 shares of Eli Lilly worth $5.75M as of Q2 2026.
- RB Capital Management sold 25 Eli Lilly shares in Q2 2026, an estimated $25.5K.
- Eli Lilly made up 1.12% of RB Capital Management's portfolio in Q2 2026, its #20 holding.
- RB Capital Management first reported a position in Eli Lilly in Q4 2016 and has held it in 39 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on RB Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.